Skip to content
Clinical Trials – home
Therapeutic area

Vascular disorders – page 24

  • 838 clinical trials
  • 353 recruiting
  • 378 conditions
  • 28 countries

Conditions in this area

378 conditions with trials, the busiest first

Clinical trials in Vascular disorders

838 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

838 clinical trials

VEXAS syndrome

Recruiting

Study of Azacitidine Treatment in Patients with VEXAS Syndrome

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Region Hovedstaden

Study on Esmolol Hydrochloride, Dobutamine, and Milrinone for Patients with Cardiogenic Shock on V-A ECMO Support

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Dobutamine
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Study on Reducing Antiplatelet Therapy in Patients with Acute Coronary Syndrome and High Bleeding Risk Using Prasugrel, Ticagrelor, or Clopidogrel

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Azienda Ospedaliera Universitaria Gaetano Martino Messina

Study on Dual Antiplatelet Therapy Duration for Patients with Chronic Coronary Artery Blockage Using Clopidogrel and D,L-Lysine Acetylsalicylate

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Clopidogrel
  • Sponsor:Centre Hospitalier Regional De Marseille

Study on Treating Calcinosis Cutis in Systemic Sclerosis Patients with Sodium Thiosulfate, Cetrimide, and Lidocaine

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Cetrimide
  • Sponsor:Region Midtjylland

Study on Propranolol and Pembrolizumab for Patients with Advanced Angiosarcoma and Undifferentiated Pleomorphic Sarcoma

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Region Hovedstaden

Diabetic foot

Recruiting

Study on the Use of Plasma Rich in Growth Factors for Treating Foot Ulcers in Diabetic Patients with Peripheral Arterial Disease

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Platelet Concentrate
  • Sponsor:Biotechnology Institute I Mas D S.L.

Study on the Effectiveness of Oxygen for Patients with Intermediate-Risk Acute Pulmonary Embolism

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Oxygen
  • Sponsor:Fundacion Para La Investigacion Biomedica Del Hospital Universitario Ramon Y Cajal

Study on Dornase Alfa and Placebo to Reduce ARDS in Ventilated Trauma Patients in ICU

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dornase Alfa
  • Sponsor:Les Hopitaux Universitaires De Strasbourg

Peritonitis+2

Recruiting

Study on the Effects of Immunoglobulin A, G, and M in Patients with Peritonitis and Sepsis After Infection Control

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Immunoglobulin A
  • Sponsor:Universitaetsklinikum Aachen AöR

Study of Narsoplimab for Children with High-Risk Blood Vessel Damage After Stem Cell Transplant

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Narsoplimab
  • Sponsor:Omeros Corp.

Study on Enalapril for Adults with Painful Venous Malformations

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Enalapril Maleate
  • Sponsor:Oslo University Hospital HF

Substances studied in this area

The therapies tested most often in Vascular disorders trials.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.